Ripretinib
Ripretinib is listed in the FDA National Drug Code directory with 5 NDC codes, marketed under brand name including QINLOCK. Available dosage forms: tablet, powder.
Drug Details
- Generic Name
- Ripretinib
- Brand Names
- QINLOCK
- Application Number
- NDA213973
- Sponsor
- Deciphera Pharmaceuticals, LLC
- NDC Codes
- 5
- Dosage Forms
- TABLET, POWDER
- Routes
- ORAL
- Active Ingredients
- RIPRETINIB
Indications and Usage
1 INDICATIONS AND USAGE QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. ( 1 )